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It has previously been demonstrated that the presence of fetal bovine serum is necessary for TGF-β3 (trans-
forming growth factor beta 3)-dependent elimination of low-dose hyper-radiosensitivity (HRS) in cells by 1 h
of low-dose-rate γ-irradiation (0.2–0.3 Gy/h). The purpose of the present study was to identify the serum con-
stituent involved. Two human HRS-positive (T-47D, T98G) cell lines were used. The effects of different pre-
treatments on HRS were investigated using the colony assay. Total inducible nitric oxide synthase (iNOS)
levels were measured using a cell-based ELISA assay. The serum factor was identified as interleukin-13 (IL-13).
In order for low dose-rate irradiation to eliminate HRS through the TGF-β3-dependent mechanism, the cells
must be exposed to IL-13 first. Inhibiting receptor IL-13Rα2 showed that this receptor is involved in the re-
sponse. Adding IL-13 to serum-free medium restored the properties of full medium but not when an inhibitor
of proprotein convertase activity was added together with IL-13. The presence of IL-13 resulted in upregula-
tion of total iNOS protein levels. Thus, this study indicates that IL-13 interacts with the cells though receptor
IL-13Rα2 and induces upregulation of iNOS and activation of one or more furin-like proprotein convertases.
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INTRODUCTION
Low-dose hyper-radiosensitivity (HRS) is, in all probability,
the default response of cells to small doses of both high- and
low-LET (linear energy transfer) ionizing radiations [1].
HRS is characterized by a high sensitivity per unit dose for
doses below ~0.5 Gy. For low-LET radiation, this is followed
by a more resistant response in the dose range ~0.5–1 Gy,
called ‘increased radioresistance’ (IRR) [2, 3].
HRS is transiently removed in response to a high-dose-rate
(HDR) priming dose of 0.2–0.3 Gy [4–8]. However, previous
studies from our laboratory have shown that by protracting
the delivery of a priming dose of 0.06–0.3 Gy to 1 h (LDR),
the effect on HRS in T-47D breast cancer cells and T98G
glioblastoma cells becomes permanent [4, 9]. The effect of
LDR irradiation was found to depend on TGF-β3 (transform-
ing growth factor beta 3), which turned off the HRS response
in the cells [9]. In cells receiving medium from LDR-
irradiated cells, as well as in cells receiving LDR-irradiated
cell conditioned medium (medium conditioned on unirra-
diated cells, filtered and irradiated without cells present) or
medium supplemented with recombinant TGF-β3, the effect
on the HRS was transient. However, in cells that were LDR
irradiated themselves, the HRS-response was removed per-
manently. Both the mechanism that induced the non-HRS re-
sponse and the mechanism maintaining the non-HRS
response were found to depend on iNOS activation and per-
oxynitrite generation from nitric oxide (NO) and superoxide
[9, 10].
LDR irradiation had no effect on HRS if the cells were cul-
tured in medium without fetal bovine serum. Also, the
removal of HRS in cells receiving LDR-irradiated cell condi-
tioned medium depended on the presence of serum during
conditioning of the medium, but not during LDR irradiation
[10].
Interleukin-13 (IL-13) is a pleiotropic immune regulatory
cytokine with many characteristics in common with
interleukin-4 (IL-4). The effect of both these cytokines is
mediated through a cell surface receptor system consisting of
IL-4 receptor α (IL−4Rα) and IL-13Rα1, which induces
signal transduction through the Janus-activated kinase (JAK)/
signal transducer and activator of transcription 6 (STAT6)
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Fig. 1. The effect on radiation response of pretreatments using interleukins in serum-free medium with or without LDR
priming irradiation. The response was measured by surviving fractions as a function of HDR challenge dose (~30 Gy/h).
(A) LDR priming irradiation of T-47D cells with serum-free medium with (closed triangles) or without (closed squares)
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pathway [11, 12]. IL-13 also binds to IL-13Rα2 with high af-
finity. This receptor was long thought to be a decoy receptor,
with its main function being sequestering IL-13 to prevent
binding to IL-13Rα1 [13]. However, IL-13Rα2 has been
found to activate an AP-1 variant containing c-jun and Fra-2
[14], to induce iNOS (inducible nitric oxide synthase) upregu-
lation [15, 16] and to be involved in the conversion of
pro-furin to active furin [17]. Mandal and Levine found that
whether IL-13Rα2 functions as an inhibitory decoy receptor
depends on its relative expression being high compared with
IL-13Rα1, and that cells with low levels of the receptor
respond to IL-13 by biasing the cell toward enhanced MAPK
signaling [18].
The aims of the present study were to find the putative
factor in fetal bovine serum requisite for LDR irradiation to
have an effect.
MATERIALS ANDMETHODS
Cell culture
Cells of two human HRS-positive cell lines (T-47D breast
cancer cells and T98G glioblastoma cells) were used. The
culture conditions were as described previously [4, 10, 19]
using RPMI1640 (Roswell Park Memorial Institute) medium
(JRH Biosciences, Kansas, USA) supplemented with 10%
fetal calf serum (Gibco, Paisley, UK), 2 mM L-glutamine
(SIGMA, St Louis, MO, USA), 200 units l−1 insulin
(SIGMA), and 1% C. The cells were kept in exponential
growth by reculturing of stock cultures two times a week. The
cells were tested negative for the presence of mycoplasma.
In experiments with interleukins 4 or 13 (IL4–10H and
IL13–22H, Creative Biomart, NY 11967, USA), the cells
were washed three times with serum-free medium before
serum-free medium with 10 ng/ml interleukin was added for
cell conditioning and LDR priming. Fetal calf serum (10%)
was added 1 h after the end of irradiation.
Decanoyl-RVKR-CMK (Tocris Bioscience, Bristol, BS11
0QL, UK) (20 μM) was used to block the activity of all
seven proprotein convertases (PC1, PC2, PC4, PACE4, PC5,
PC7 and furin). It was added together with 10 ng/ml IL-13 in
serum-free medium to the cells 4 h before LDR priming. The
medium was exchanged with normal full medium 1 h after
the end of irradiation.
IL-13, IL-13Rα2 and TGF-β3 neutralizing antibodies
were purchased from R&D (R&D systems, Minneapolis,
MN, USA).
Irradiation procedures
The cells were irradiated as described previously (19). The
high dose rate (HDR) was ~ 30 Gy/h as in previous reports,
but because of [60Co]-decay, the low dose rate (LDR) used in
the present experiments was ~0.2 Gy/h (compared with 0.3
Gy/h in our previous studies). The total LDR irradiation time
was 1 h, so the total dose in all LDR radiations was ~0.2 Gy.
Transfer of cell-conditioned medium irradiated
without cells present
The medium transfer experiments in Fig. 2 were performed
as described previously [10, 19] and summarized in Fig. 2A.
Cell survival
The surviving fraction was determined by counting the
number of colonies containing more than 50 cells as
described previously [19].
Statistical analysis
All experiments were repeated at least three times, using five
flasks for each challenge dose and 10 for controls. Within
each experiment, the arithmetic means were calculated,
weighing the errors. Radiation survival curve data were fitted
using the linear quadratic (LQ) or the induced repair (IR)
model [4, 10, 19].
The two-tailed Student’s t-test was used to compare the
surviving fractions in response to the HDR challenge irradi-
ation of pretreated cells compared with the controls or
LDR-irradiated cells.
Cell-based ELISA
The total iNOS levels in whole cells were measured by an
ELISA-based assay using fluorogenic substrates according
to the manufacturer’s protocol (KCB9502, R&D systems,
Minneapolis, MN, USA). Cells were grown overnight in
microplates with or without IL-13 antibody (3 μg/ml) and
fixed and permeabilized with 4% formaldehyde. The cells
were then incubated simultaneously with two primary anti-
bodies (iNOS and GAPDH for normalization) and thereafter
addition of 10 ng/ml IL-13, 40 h before HDR challenge irradiation (P < 0.01 for 0.2, 0.3 and 2 Gy, P = 0.02 for 5 Gy). The
curves represent model-fits to the data from unprimed cells by the IR-model (solid lines) and the LQ-model (dashed lines),
respectively. The bars represent standard errors of the mean (SEM) for three to seven individual experiments. T-47D (B)
and T98G (C) cells pretreated with LDR priming irradiation of cells with serum-free medium supplemented with 10 ng/ml
IL-4 (white), serum-free medium supplemented with 10 ng/ml IL-13 but no priming irradiation (densely hatched), LDR
priming irradiation of cells with serum-free medium with 10 ng/ml IL-13, 24 h before HDR challenge irradiation (sparsely
hatched), LDR priming irradiation of cells with serum-free medium with 10 ng/ml IL-13, 7 weeks before HDR challenge
irradiation (checkered). Data from untreated cells are shown as reference (black). Two asterisks indicate P < 0.01; three
asterisks indicate P < 0.001. The bars represent SEM for three individual experiments. (D) Timeline showing the
experimental schedules.
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with two secondary antibodies (horseradish-peroxidase and al-
kaline phosphatase). The fluorescence was measured using a
Synergy 2 Multi-Mode Microplate Reader (BioTek, Winooski,
VT, USA), and the fluorescence of iNOS was normalized to
that of GAPDH for each well after background subtraction.
RESULTS
From previous experiments, it was known that the presence
of serum was essential for LDR irradiation to have an effect
on HRS [10]. In order to identify the factor required in the
serum, interleukins 4 and 13 were tested on both T-47D cells
(Fig. 1A and B) and T98G cells (Fig. 1C). In Fig. 1A, the
full dose–response curve of the HRS region is shown for
cells that were LDR-primed with serum-free medium with or
without IL-13. It indicates that IL-13 can replace serum for
the effect of LDR priming to HRS. In Fig. 1B and C, the two
doses within the HRS range with the largest difference in sur-
vival of HRS-positive and HRS-negative cells, 0.2 and 0.3
Gy, were used as challenge doses. IL-13 in serum-free
medium did not influence radiosensitivity itself. However,
the presence of IL-13 in serum-free medium was sufficient to
make LDR irradiation induce resistance to HDR challenge
doses of 0.2 and 0.3 Gy, even 7 weeks after priming irradi-
ation. LDR irradiation of cells with serum-free medium with
IL-4 did not influence radiosensitivity.
Figure 2 shows data from exposing cells to medium,
which had first been conditioned without serum on unirra-
diated cells and then LDR irradiated without serum or cells
present (experimental design is shown in Fig. 2A). A previ-
ous study [10] showed that when full medium was used, this
resulted in elimination of HRS in recipient cells. As seen in
Fig. 2B, cells receiving medium that was cell conditioned
and LDR irradiated without serum present, retained the HRS
response. However, when the experiment was repeated with
IL-13 added to the serum-free medium during cell condition-
ing (and priming), the recipient cells lost the HRS response
when tested 40 h after the end of exposure to the transferred
medium. Contrary to when the cells (and not only cell-
conditioned medium) were LDR primed (Fig. 1 B and C
(checkered)), the effect did not last and HRS was regained
when tested 2 weeks later (Fig. 2B (checkered)). This is
similar to observations using cell-conditioned serum-
containing full medium [10].
We have previously shown that TGF-β3 is involved in the
response to LDR irradiation [20]. The presence of a TGF-β3
neutralizer inhibited the effect of LDR-priming irradiation,
and the cytoplasmic levels of TGF-β3 were found to be sig-
nificantly higher in LDR-primed cells than in unprimed
control cells. In addition, recombinant TGF-β3 was found to
remove HRS in unprimed cells [20]. Since IL-13 without
LDR irradiation did not affect the HRS-response (Fig. 1B and
C), it is possible that IL-13 is involved in proactivation of the
TGF-β3-dependent mechanism before final activation by
LDR irradiation. Concentrations as low as 0.001 ng/ml
TGF-β3 have previously been found to remove HRS [20].
However, due to the sensitivity of the ELISA assay for TGF-
β3, only concentrations at least 100 times higher could be
measured by this method [20].We therefore had to use a more
indirect method to test the involvement of IL-13 in TGF-β3
activation and added TGF-β3–neutralizer to cell-conditioned
serum-free medium with IL-13 before LDR irradiation (Step 2
in Fig. 2A). This prevented the removal of HRS in the recipi-
ent cells.
In order to test whether IL-13 was the only constituent of
serum with the observed effect, a neutralizing antibody was
added the day before LDR priming of cells with full medium
(Fig. 3A). These cells did not lose the HRS response, con-
firming that IL-13 is indeed solely responsible for the effect.
Since IL-13 and not IL-4 was able to influence to ability
of the cells and medium to respond to LDR irradiation, it
was hypothesized that the effect was mediated by receptor
IL-13Rα2, which is specific for IL-13. This was confirmed
by inhibiting the receptor using an IL-13Rα2-antibody 1 h
before and during LDR priming, which disrupted the effect
of the LDR priming (Fig. 3B).
TGF-β isoforms are synthesized as homodimeric propro-
teins (proTGF-β) that consist of TGF-β covalently bound to
the latency-associated protein (LAP). The covalent binding
is cleaved (by furin-type enzymes of the proprotein conver-
tase family) as a proactivation, leaving TGF-β non-
covalently associated with LAP in an inactive state. We
hypothesized that IL-13 contributes to the proactivation of
TGF-β3 by activating a proprotein convertase. Decanoyl-
RVKR-CMK blocks the activity of all seven members of the
proprotein convertase family. When this was added to the
cell in serum-free medium together with IL-13, subsequent
LDR priming did not remove HRS (Fig. 4). These results
support the hypothesis that IL-13 activates one or more
members of the proprotein convertase family.
We have previously shown that the effect of LDR irradi-
ation on HRS is mediated by iNOS activation [9]. The re-
quirement of IL-13 for LDR irradiation to have an effect
might therefore be linked to iNOS upregulation. In order to
test this, a cell-based ELISA assay was used to measure total
iNOS levels in cells with and without IL-13 neutralizing
antibody. For both T98G and T-47D cells, the iNOS levels
were significantly reduced in cells exposed to IL-13 neutral-
izing antibody (Fig. 5). The relative amounts were
0.65 ± 0.02 for T98G cells (P = 4.7 × 10−6) and 0.65 ± 0.03
for T-47D cells (P = 6.3 × 10−6).
DISCUSSION
The present study is to our knowledge the first to show in-
volvement of IL-13 in the radiation response of cultured cells.
The requirement for fetal calf serum in medium for LDR
irradiation to remove HRS indicated the presence of a factor
IL-13 and HRS 1069
Fig. 2. The response to HDR challenge irradiation of cells receiving medium that was conditioned without serum on
unirradiated cells in the presence of IL-13 and subsequently priming irradiated without cells present. (A) Experimental
design: serum-free medium was first conditioned on unirradiated cells (Step 1). It was then removed from the cells, filtered
(0.22 μm) and LDR irradiated (0.2 Gy/h) for 1 h (Step 2). Immediately following irradiation, the medium was supplied with
10% serum and added to untreated (recipient) cells (Step 3). The recipient cells were exposed to the transferred medium for
24 h before being seeded for colony formation in fresh medium for 16–20 h before challenge irradiation. For the
experiments shown in the checkered bars in Fig. 2C, the recipient cells were given medium exchange after being exposed to
the transferred medium for 24 h. They were then cultured for 2 weeks (with 2-weekly re-seedings) before being seeded for
colony formation and challenge irradiation. (B) T47D cells: serum-free medium, which had been cell conditioned (Step 1 in
panel A) with (closed triangles) or without (closed squares) 10 ng/ml IL-13 for 24 h, and LDR irradiated for 1 h (Step 2 in
panel A) with (closed circles) or without 2 μg/ml TGF-β3 neutralizer (P < 0.01 for 0.2 and 0.3 Gy, P < 0.05 for 0.5 Gy
comparing cells receiving irradiated medium first conditioned with (closed circles) or without (closed triangles) IL-13;
P < 0.01 for 0.3 Gy, P < 0.05 for 0.2 and 0.5 Gy comparing cells receiving medium conditioned with IL-13 and irradiated
with (closed circles) or without (closed triangles) TGF-β3 neutralizer. The curves represent model-fits to the data from
unprimed cells by the IR-model (solid lines) and the LQ-model (dashed lines), respectively. The bars represent standard
errors of the mean (SEM) for three individual experiments. (C) T98G cells: serum-free medium, that had been cell
conditioned with 10 ng/ml IL-13 (shown as closed triangles in panel B). The recipient cells were seeded for colony
formation and challenge irradiation, either directly after 24-h exposure to the transferred medium, as shown in panel A
(hatched), or 2 weeks after (checkered) (see details under (A)). Data from untreated cells are shown as reference (black).
Three asterisks indicate P < 0.001. The bars represent SEM for three individual experiments.
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in the blood of fetal calves that was not produced by our cul-
tured cells. We hypothesized that this factor could be related
to the immune system, and literature studies led to two pos-
sible candidates: IL-4 and IL-13. While IL-4 had no effect,
adding IL-13 to serum-free medium restored the qualities of
full serum medium with respect to the effects of LDR irradi-
ation, indicating that IL-13 is the responsible factor in serum.
The data from neutralizing IL-13 in full-serum medium
(figure 3A) in combination with the data from adding IL-13
to serum free medium (figures 1 and 2) indicate that IL-13
alone may be responsible for the studied effect of serum.
Since IL-13 but not Il-4 binds to receptor IL-13Rα2, we
tested inhibition of IL-13Rα2 and found that this receptor
was indeed the mediator for the effect of IL-13. IL-13Rα2
has previously been seen to induce iNOS [15, 16]. In agree-
ment with this, we found a reduced level of total iNOS
protein in cells treated with IL-13-neutralizing antibody. We
have previously shown that iNOS is activated in response to
LDR irradiation and that peroxynitrite produced by super-
oxide and iNOS-generated NO is involved in mediating abo-
lition of HRS [9]. This was the case both in the permanent
effect of direct LDR irradiation of cells and in LDR
Fig. 3. The response to HDR challenge irradiation in cells LDR primed during inhibition of IL-13 or receptor IL-13Rα2. (A)
Full medium with 3 μg/ml IL-13-neutralizing antibody was added to T98G cells 24 h prior to LDR priming irradiation (closed
squares). Data for LDR-primed cells without antibody are redrawn from a previous study [9] (open circles) (P = 0.05 for 0.2 Gy,
P = 0.02 for 0.3 Gy, comparing cells LDR primed with or without IL-13-neutralizing antibody). (B) T-47D cells were washed
three times in serum-free medium and then LDR primed after transfer of full medium with (closed circles) or without (closed
triangles) receptor IL-13Rα2 neutralizing antibody (P < 0.001 for 0.3 Gy, P < 0.05 for 0.2 and 0.5 Gy). The curves represent
model-fits to the data from unprimed cells by the IR-model (solid lines) and the LQ-model (dashed lines), respectively. The
bars represent standard errors of the mean (SEM) for three individual experiments. (C) Timeline showing the experimental
schedules.
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irradiation of cell-conditioned medium resulting in a transi-
ent removal of HRS in recipient cells. Since the present data
show that IL-13 is necessary for the effect of LDR irradiation
in both cases, we hypothesized that the requirement for
IL-13 in the medium for LDR irradiation to have the
observed effect is in part due to a requirement for iNOS upre-
gulation.
We have previously shown that TGF-β3 is activated by
LDR irradiation and that TGF-β3 removes HRS [20]. The
three TGF-β isoforms are all synthesized as homodimeric
proproteins (proTGF-β) that have a mass of 75 kDa and
consist TGF-β and LAP. The LAP is cleaved from the
mature TGF-β 24-kDa dimer in the trans Golgi by furin-type
enzymes as a proactivation, leaving TGF-β non-covalently
associated with LAP in an inactive state [21]. In our previous
study [20], we proposed that reactive oxygen species (ROS)
produced by radiation can activate the proactivated
non-covalently-associated TGF-β3, but that NO is required
Fig. 4. The response to HDR challenge irradiation in cells that were LDR primed in the presence of IL-13 as well as
pro-protein convertase inhibitor Decanoyl-RVKR-CMK. (A) T47D cells were LDR irradiated in serum-free medium
with10 ng/ml IL-13 and with (closed triangles) or without (replotted from Fig. 1A; closed squares) 20μM
Decanoyl-RVKR-CMK, 44–20 h before HDR challenge irradiation (P = 0.05 for 0.5 and 2 Gy, P < 0.01 for all other doses).
The curves represent model-fits to the data from unprimed cells by the IR-model (solid lines) and the LQ-model (dashed
lines), respectively. The bars represent standard errors of the mean (SEM) for five individual experiments. (B) Timeline
showing the experimental schedules.
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for scavenging LAP in order to prevent reassociation
between TGF-β and LAP. Thus, it is likely that IL-13 is
required to secure available iNOS to produce enough NO in
response to LDR irradiation in order for LAP to be sca-
venged before reassociation to TGF-β3.
Liu et al. showed that receptor IL-13Rα2 is involved in
the conversion of pro-furin to active furin [17]. Thus IL-13
could also be involved in the first step of proactivation of the
TGF-β3-LAP complex. We were not able to detect any dif-
ference in furin levels in our cells using flow cytometry (data
not shown). However, the supplier of the antibody (R&D
systems, Minneapolis, MN, USA) could not exclude cross-
reactivity with pro-furin. We therefore tried general inhib-
ition of all seven members of the proprotein convertase
family to which furin belongs and found that at least one of
these was required for LDR priming to remove HRS. IL-13
thus appears to activate one or more enzymes of the furin
family.
We propose that the active furin-like enzyme leads to
proactivation of the TGFβ3-LAP complex as a prerequisite
for TGF-β3 activation by LDR irradiation, which involves
iNOS activation. The role of IL-13 appears thus to be two-
sided: it proactivates TGF-β3 and facilitates activation by
LDR irradiation by upregulation of iNOS.
In conclusion, we have shown that IL-13 is not produced
by cultured cells but is present in the fetal calf serum used in
cell culture. IL-13 interacts with the cells though receptor
IL-13Rα2 and induces upregulation of iNOS and activation
of one or more furin-like proprotein convertases.
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